Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
54
BBP Quote, Financials, Valuation and Earnings
Last price:
$83.23
Seasonality move
:
6.44%
Day range:
$83.04 - $84.22
52-week range:
$48.65 - $87.17
Dividend yield:
0.09%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
2.7K
Avg. volume:
8.1K
1-year change:
43.95%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BBP
Virtus Biotech ETF
|
-- | -- | -- | -- | -- |
|
BBC
Virtus Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
PFFR
InfraCap REIT Preferred ETF
|
-- | -- | -- | -- | -- |
|
PTH
Invesco Dorsey Wright Healthcare Momentum ETF
|
-- | -- | -- | -- | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BBP
Virtus Biotech ETF
|
$83.70 | -- | -- | -- | $0.00 | 0.09% | -- |
|
BBC
Virtus Biotech Clinical Trials ETF
|
$42.84 | -- | -- | -- | $0.66 | 1.51% | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
$44.19 | -- | -- | -- | $0.59 | 1.35% | -- |
|
PFFR
InfraCap REIT Preferred ETF
|
$17.25 | -- | -- | -- | $0.12 | 8.39% | -- |
|
PTH
Invesco Dorsey Wright Healthcare Momentum ETF
|
$49.70 | -- | -- | -- | $1.53 | 3.06% | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
$128.96 | -- | -- | -- | $0.41 | 0.35% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BBP
Virtus Biotech ETF
|
-- | 0.162 | -- | -- |
|
BBC
Virtus Biotech Clinical Trials ETF
|
-- | 0.327 | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | 0.930 | -- | -- |
|
PFFR
InfraCap REIT Preferred ETF
|
-- | 0.300 | -- | -- |
|
PTH
Invesco Dorsey Wright Healthcare Momentum ETF
|
-- | 0.065 | -- | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | 0.103 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BBP
Virtus Biotech ETF
|
-- | -- | -- | -- | -- | -- |
|
BBC
Virtus Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
PFFR
InfraCap REIT Preferred ETF
|
-- | -- | -- | -- | -- | -- |
|
PTH
Invesco Dorsey Wright Healthcare Momentum ETF
|
-- | -- | -- | -- | -- | -- |
|
XBI
State Street SPDR S&P Biotech ETF
|
-- | -- | -- | -- | -- | -- |
Virtus Biotech ETF vs. Competitors
-
Which has Higher Returns BBP or BBC?
Virtus Biotech Clinical Trials ETF has a net margin of -- compared to Virtus Biotech ETF's net margin of --. Virtus Biotech ETF's return on equity of -- beat Virtus Biotech Clinical Trials ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBPVirtus Biotech ETF-- -- -- BBCVirtus Biotech Clinical Trials ETF-- -- -- -
What do Analysts Say About BBP or BBC?
Virtus Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus Biotech Clinical Trials ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus Biotech ETF has higher upside potential than Virtus Biotech Clinical Trials ETF, analysts believe Virtus Biotech ETF is more attractive than Virtus Biotech Clinical Trials ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBPVirtus Biotech ETF0 0 0 BBCVirtus Biotech Clinical Trials ETF0 0 0 -
Is BBP or BBC More Risky?
Virtus Biotech ETF has a beta of 0.662, which suggesting that the stock is 33.751% less volatile than S&P 500. In comparison Virtus Biotech Clinical Trials ETF has a beta of 0.974, suggesting its less volatile than the S&P 500 by 2.575%.
-
Which is a Better Dividend Stock BBP or BBC?
Virtus Biotech ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0.09%. Virtus Biotech Clinical Trials ETF offers a yield of 1.51% to investors and pays a quarterly dividend of $0.66 per share. Virtus Biotech ETF pays -- of its earnings as a dividend. Virtus Biotech Clinical Trials ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBP or BBC?
Virtus Biotech ETF quarterly revenues are --, which are smaller than Virtus Biotech Clinical Trials ETF quarterly revenues of --. Virtus Biotech ETF's net income of -- is lower than Virtus Biotech Clinical Trials ETF's net income of --. Notably, Virtus Biotech ETF's price-to-earnings ratio is -- while Virtus Biotech Clinical Trials ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus Biotech ETF is -- versus -- for Virtus Biotech Clinical Trials ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBPVirtus Biotech ETF-- -- -- -- BBCVirtus Biotech Clinical Trials ETF-- -- -- --
-
Which has Higher Returns BBP or GNOM?
Global X Genomics & Biotechnology ETF has a net margin of -- compared to Virtus Biotech ETF's net margin of --. Virtus Biotech ETF's return on equity of -- beat Global X Genomics & Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBPVirtus Biotech ETF-- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -
What do Analysts Say About BBP or GNOM?
Virtus Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Genomics & Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus Biotech ETF has higher upside potential than Global X Genomics & Biotechnology ETF, analysts believe Virtus Biotech ETF is more attractive than Global X Genomics & Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBPVirtus Biotech ETF0 0 0 GNOMGlobal X Genomics & Biotechnology ETF0 0 0 -
Is BBP or GNOM More Risky?
Virtus Biotech ETF has a beta of 0.662, which suggesting that the stock is 33.751% less volatile than S&P 500. In comparison Global X Genomics & Biotechnology ETF has a beta of 1.289, suggesting its more volatile than the S&P 500 by 28.945%.
-
Which is a Better Dividend Stock BBP or GNOM?
Virtus Biotech ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0.09%. Global X Genomics & Biotechnology ETF offers a yield of 1.35% to investors and pays a quarterly dividend of $0.59 per share. Virtus Biotech ETF pays -- of its earnings as a dividend. Global X Genomics & Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBP or GNOM?
Virtus Biotech ETF quarterly revenues are --, which are smaller than Global X Genomics & Biotechnology ETF quarterly revenues of --. Virtus Biotech ETF's net income of -- is lower than Global X Genomics & Biotechnology ETF's net income of --. Notably, Virtus Biotech ETF's price-to-earnings ratio is -- while Global X Genomics & Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus Biotech ETF is -- versus -- for Global X Genomics & Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBPVirtus Biotech ETF-- -- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- --
-
Which has Higher Returns BBP or PFFR?
InfraCap REIT Preferred ETF has a net margin of -- compared to Virtus Biotech ETF's net margin of --. Virtus Biotech ETF's return on equity of -- beat InfraCap REIT Preferred ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBPVirtus Biotech ETF-- -- -- PFFRInfraCap REIT Preferred ETF-- -- -- -
What do Analysts Say About BBP or PFFR?
Virtus Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand InfraCap REIT Preferred ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus Biotech ETF has higher upside potential than InfraCap REIT Preferred ETF, analysts believe Virtus Biotech ETF is more attractive than InfraCap REIT Preferred ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBPVirtus Biotech ETF0 0 0 PFFRInfraCap REIT Preferred ETF0 0 0 -
Is BBP or PFFR More Risky?
Virtus Biotech ETF has a beta of 0.662, which suggesting that the stock is 33.751% less volatile than S&P 500. In comparison InfraCap REIT Preferred ETF has a beta of 0.697, suggesting its less volatile than the S&P 500 by 30.277%.
-
Which is a Better Dividend Stock BBP or PFFR?
Virtus Biotech ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0.09%. InfraCap REIT Preferred ETF offers a yield of 8.39% to investors and pays a quarterly dividend of $0.12 per share. Virtus Biotech ETF pays -- of its earnings as a dividend. InfraCap REIT Preferred ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBP or PFFR?
Virtus Biotech ETF quarterly revenues are --, which are smaller than InfraCap REIT Preferred ETF quarterly revenues of --. Virtus Biotech ETF's net income of -- is lower than InfraCap REIT Preferred ETF's net income of --. Notably, Virtus Biotech ETF's price-to-earnings ratio is -- while InfraCap REIT Preferred ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus Biotech ETF is -- versus -- for InfraCap REIT Preferred ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBPVirtus Biotech ETF-- -- -- -- PFFRInfraCap REIT Preferred ETF-- -- -- --
-
Which has Higher Returns BBP or PTH?
Invesco Dorsey Wright Healthcare Momentum ETF has a net margin of -- compared to Virtus Biotech ETF's net margin of --. Virtus Biotech ETF's return on equity of -- beat Invesco Dorsey Wright Healthcare Momentum ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBPVirtus Biotech ETF-- -- -- PTHInvesco Dorsey Wright Healthcare Momentum ETF-- -- -- -
What do Analysts Say About BBP or PTH?
Virtus Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Dorsey Wright Healthcare Momentum ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus Biotech ETF has higher upside potential than Invesco Dorsey Wright Healthcare Momentum ETF, analysts believe Virtus Biotech ETF is more attractive than Invesco Dorsey Wright Healthcare Momentum ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBPVirtus Biotech ETF0 0 0 PTHInvesco Dorsey Wright Healthcare Momentum ETF0 0 0 -
Is BBP or PTH More Risky?
Virtus Biotech ETF has a beta of 0.662, which suggesting that the stock is 33.751% less volatile than S&P 500. In comparison Invesco Dorsey Wright Healthcare Momentum ETF has a beta of 0.918, suggesting its less volatile than the S&P 500 by 8.198%.
-
Which is a Better Dividend Stock BBP or PTH?
Virtus Biotech ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0.09%. Invesco Dorsey Wright Healthcare Momentum ETF offers a yield of 3.06% to investors and pays a quarterly dividend of $1.53 per share. Virtus Biotech ETF pays -- of its earnings as a dividend. Invesco Dorsey Wright Healthcare Momentum ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBP or PTH?
Virtus Biotech ETF quarterly revenues are --, which are smaller than Invesco Dorsey Wright Healthcare Momentum ETF quarterly revenues of --. Virtus Biotech ETF's net income of -- is lower than Invesco Dorsey Wright Healthcare Momentum ETF's net income of --. Notably, Virtus Biotech ETF's price-to-earnings ratio is -- while Invesco Dorsey Wright Healthcare Momentum ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus Biotech ETF is -- versus -- for Invesco Dorsey Wright Healthcare Momentum ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBPVirtus Biotech ETF-- -- -- -- PTHInvesco Dorsey Wright Healthcare Momentum ETF-- -- -- --
-
Which has Higher Returns BBP or XBI?
State Street SPDR S&P Biotech ETF has a net margin of -- compared to Virtus Biotech ETF's net margin of --. Virtus Biotech ETF's return on equity of -- beat State Street SPDR S&P Biotech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BBPVirtus Biotech ETF-- -- -- XBIState Street SPDR S&P Biotech ETF-- -- -- -
What do Analysts Say About BBP or XBI?
Virtus Biotech ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand State Street SPDR S&P Biotech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Virtus Biotech ETF has higher upside potential than State Street SPDR S&P Biotech ETF, analysts believe Virtus Biotech ETF is more attractive than State Street SPDR S&P Biotech ETF.
Company Buy Ratings Hold Ratings Sell Ratings BBPVirtus Biotech ETF0 0 0 XBIState Street SPDR S&P Biotech ETF0 0 0 -
Is BBP or XBI More Risky?
Virtus Biotech ETF has a beta of 0.662, which suggesting that the stock is 33.751% less volatile than S&P 500. In comparison State Street SPDR S&P Biotech ETF has a beta of 0.925, suggesting its less volatile than the S&P 500 by 7.529%.
-
Which is a Better Dividend Stock BBP or XBI?
Virtus Biotech ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0.09%. State Street SPDR S&P Biotech ETF offers a yield of 0.35% to investors and pays a quarterly dividend of $0.41 per share. Virtus Biotech ETF pays -- of its earnings as a dividend. State Street SPDR S&P Biotech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BBP or XBI?
Virtus Biotech ETF quarterly revenues are --, which are smaller than State Street SPDR S&P Biotech ETF quarterly revenues of --. Virtus Biotech ETF's net income of -- is lower than State Street SPDR S&P Biotech ETF's net income of --. Notably, Virtus Biotech ETF's price-to-earnings ratio is -- while State Street SPDR S&P Biotech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Virtus Biotech ETF is -- versus -- for State Street SPDR S&P Biotech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BBPVirtus Biotech ETF-- -- -- -- XBIState Street SPDR S&P Biotech ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
